MX2021003905A - Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. - Google Patents

Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.

Info

Publication number
MX2021003905A
MX2021003905A MX2021003905A MX2021003905A MX2021003905A MX 2021003905 A MX2021003905 A MX 2021003905A MX 2021003905 A MX2021003905 A MX 2021003905A MX 2021003905 A MX2021003905 A MX 2021003905A MX 2021003905 A MX2021003905 A MX 2021003905A
Authority
MX
Mexico
Prior art keywords
orlistat
acarbose
obesity
treatment
release composition
Prior art date
Application number
MX2021003905A
Other languages
English (en)
Inventor
Göran Alderborn
Anders Forslund
Hans Lennernäs
Jan Stefan Persson Grudén
Ulf Holmbäck
Original Assignee
Empros Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021003905(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Empros Pharma Ab filed Critical Empros Pharma Ab
Publication of MX2021003905A publication Critical patent/MX2021003905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una composición de liberación modificada que comprende orlistat y acarbosa, que comprende partes individualmente distintas con diferentes patrones de liberación: a) una primera parte, G1, que comprende de aproximadamente 5 a aproximadamente 70% p/p de la dosis total de acarbosa, b) una segunda parte, G2A, que comprende de aproximadamente 30 a aproximadamente 95% p/p de la dosis total de acarbosa, c) una tercera parte, G2B, que comprende de aproximadamente 10 a aproximadamente 90% p/p de la dosis total de orlistat, y d) una cuarta parte, G3, que comprende de aproximadamente 10 a aproximadamente 80% p/p de la dosis total de orlistat, y la concentración total de acarbosa y orlistat, respectivamente, en la composición es de 100% p/p.
MX2021003905A 2014-12-17 2017-06-08 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados. MX2021003905A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14198468 2014-12-17

Publications (1)

Publication Number Publication Date
MX2021003905A true MX2021003905A (es) 2021-09-30

Family

ID=52146175

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007493A MX2017007493A (es) 2014-12-17 2015-12-17 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
MX2019001376A MX2019001376A (es) 2014-12-17 2017-06-08 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
MX2021003905A MX2021003905A (es) 2014-12-17 2017-06-08 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017007493A MX2017007493A (es) 2014-12-17 2015-12-17 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
MX2019001376A MX2019001376A (es) 2014-12-17 2017-06-08 Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.

Country Status (28)

Country Link
US (2) US10561617B2 (es)
EP (3) EP3943076A3 (es)
JP (1) JP6607955B2 (es)
KR (2) KR101937069B1 (es)
CN (1) CN107405309B (es)
AU (1) AU2015367422B2 (es)
BR (1) BR112017012714B1 (es)
CA (1) CA2970991C (es)
CL (1) CL2017001574A1 (es)
CO (1) CO2017005834A2 (es)
DK (1) DK3233066T3 (es)
EA (1) EA033448B1 (es)
EC (1) ECSP17035750A (es)
ES (1) ES2901122T3 (es)
HU (1) HUE057093T2 (es)
IL (1) IL252865B2 (es)
MX (3) MX2017007493A (es)
MY (1) MY195038A (es)
NZ (1) NZ732241A (es)
PE (1) PE20171243A1 (es)
PH (1) PH12017550023A1 (es)
PL (1) PL3233066T3 (es)
SA (1) SA517381713B1 (es)
SG (1) SG11201704470PA (es)
SI (1) SI3233066T1 (es)
UA (1) UA122403C2 (es)
WO (1) WO2016097170A1 (es)
ZA (1) ZA201704590B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943076A3 (en) 2014-12-17 2022-04-13 Empros Pharma AB A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
JP6359234B2 (ja) * 2016-06-09 2018-07-18 Ｄｓファーマアニマルヘルス株式会社 動物用徐放性製剤組成物
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
EP4072532B1 (en) * 2019-12-11 2024-01-24 Evonik Operations GmbH Dosage form for use in treating or preventing of a disease
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法
WO2022154687A1 (ru) * 2021-01-14 2022-07-21 Общество C Ограниченной Ответственностью "Новамедика" Фармацевтическая композиция, включающая эзомепразол
WO2022243528A1 (en) 2021-05-21 2022-11-24 Empros Pharma Ab Use of a composition comprising orlistat and acarbose to obtain a sustained weight loss
JP2024519099A (ja) 2021-05-21 2024-05-08 エンプロス ファーマ エービー オルリスタット及びアルカボースの組成物での、体重減少、クオリティ・オブ・ライフ改善及び胃腸管副作用の低減に対する相乗効果
CA3219508A1 (en) 2021-05-21 2022-11-24 Jan Stefan Persson Gruden Reduced rebound effects in subjects treated for overweight or obesity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8101930A (nl) 1981-04-21 1982-11-16 Philips Nv Contactinrichting voor een meeraderige kabel.
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6849609B2 (en) 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
WO2003009840A1 (en) * 2001-07-24 2003-02-06 Lonza Ag Composition comprising at least one lipase inhibitor and carnitine
CN1296050C (zh) * 2003-12-10 2007-01-24 浙江海正药业股份有限公司 阿卡波糖肠溶片及制备方法
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100857411B1 (ko) * 2006-07-21 2008-09-08 한올제약주식회사 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법
US8110186B2 (en) * 2006-09-18 2012-02-07 Chelatexx, LLC Method to maintain the efficacy of orlistat
TW200841876A (en) * 2007-04-18 2008-11-01 Anchen Pharmaceuticals Taiwan Inc Pharmaceutical composition containing orlistat
BRPI0817053A2 (pt) 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat
US20110256130A1 (en) * 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
SG184851A1 (en) * 2010-04-27 2012-11-29 Bayer Ip Gmbh Orally disintegrating tablet containing acarbose
EP2590633B1 (en) * 2010-07-05 2017-10-11 Jagotec AG Dosage form
CN102872062A (zh) 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
EP3943076A3 (en) 2014-12-17 2022-04-13 Empros Pharma AB A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

Also Published As

Publication number Publication date
DK3233066T3 (da) 2022-01-10
PE20171243A1 (es) 2017-08-24
MX2017007493A (es) 2018-01-26
KR20170090505A (ko) 2017-08-07
CL2017001574A1 (es) 2018-01-26
SI3233066T1 (sl) 2022-02-28
HUE057093T2 (hu) 2022-04-28
SA517381713B1 (ar) 2022-03-17
CA2970991A1 (en) 2016-06-23
EP3943076A3 (en) 2022-04-13
WO2016097170A1 (en) 2016-06-23
ES2901122T3 (es) 2022-03-21
SG11201704470PA (en) 2017-07-28
CN107405309B (zh) 2019-04-16
ECSP17035750A (es) 2017-08-31
NZ732241A (en) 2019-01-25
IL252865A0 (en) 2017-08-31
CN107405309A (zh) 2017-11-28
MY195038A (en) 2023-01-04
US20200230063A1 (en) 2020-07-23
AU2015367422B2 (en) 2017-11-02
KR20190004816A (ko) 2019-01-14
CO2017005834A2 (es) 2017-11-30
KR102094631B1 (ko) 2020-03-27
EP4364743A2 (en) 2024-05-08
PL3233066T3 (pl) 2022-02-14
PH12017550023A1 (en) 2017-10-18
BR112017012714B1 (pt) 2023-09-26
EP3943076A2 (en) 2022-01-26
KR101937069B1 (ko) 2019-04-03
AU2015367422A1 (en) 2017-06-15
JP6607955B2 (ja) 2019-11-20
US20170360715A1 (en) 2017-12-21
US10561617B2 (en) 2020-02-18
EP3233066A1 (en) 2017-10-25
ZA201704590B (en) 2022-03-30
IL252865B2 (en) 2023-03-01
IL252865B (en) 2022-11-01
US11975105B2 (en) 2024-05-07
EA033448B1 (ru) 2019-10-31
UA122403C2 (uk) 2020-11-10
JP2018501310A (ja) 2018-01-18
EP3233066B1 (en) 2021-11-10
EA201791348A1 (ru) 2017-09-29
MX2019001376A (es) 2019-05-30
BR112017012714A2 (pt) 2018-03-13
CA2970991C (en) 2021-08-03

Similar Documents

Publication Publication Date Title
MX2019001376A (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados.
DOP2016000195A (es) Compuestos
PH12017500746A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2018006223A (es) Moduladores de ror-gamma.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
TN2016000435A1 (en) Novel macrocyclic compounds.
PH12020550583A1 (en) Use of riluzole prodrugs to treat ataxias
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
DK3694505T3 (da) Forbindelse og sammensætning til anvendelse ved præventiv og/eller kurativ behandling af sygdomme i centralnervesystemet, der er karakteristiske ved en nedgang i den neuronale plasticitet, især karakteristiske ved en nedgang i den synaptiske plasticitet
MX2016008968A (es) Compuestos organicos.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2020012065A (es) Compuestos de ciclopentano.
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.